Comment by the Board of Directors[1] of Q-Med in relation to certain statements in media

In relation to speculations in various media on potential competing offers for
Q-Med AB (publ) ("Q-Med"), which also have led to questions from especially
international investors, the Board of Directors of Q-Med (the "Board") wants to
clarify the following. The Board has no ongoing discussions with other potential
bidders for Q-Med other than with Galderma Holding AB, a company wholly-owned by
Galderma Pharma S.A., ("Galderma"). At present, there is no interest from other
potential buyers.

This statement shall in all respects be governed by and construed in accordance
with substantive Swedish law. Disputes arising from this statement shall be
settled exclusively by Swedish courts.


Uppsala February 7, 2011
Q-Med AB (publ)
The Board of Directors


Queries should be addressed to:
Anders Milton, Chairman of the Bid Committee[2] and Director of the Board
Tel: +46 (0) 70 526 46 02


Q-Med provides the information in this release in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was submitted for disclosure at 7.30 a.m. on February 7, 2011.


Q-Med AB is a medical device company that develops, manufactures, markets, and
sells high quality medical implants for esthetic and medical use. The majority
of the products are based on the company's patented technology, NASHA(TM), for
the production of stabilized non-animal hyaluronic acid. The product portfolio
today contains: Restylane® for filling lines and folds, contouring and creating
volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta® for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q-Med today has about 650 coworkers, with almost 400 at the company's
head office and production facility in Uppsala, Sweden. Q-Med AB is listed in
the Mid Cap segment of the NASDAQ OMX Nordic.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com. Web: www.q-
med.com.


[1] In view of the undertaking from Lyftet Holding B.V. to Galderma to accept
the public offer to the shareholders of Q-Med made by Galderma (the "Offer"),
Bengt Ågerup has not participated in the Board's dealings with matters relating
to the Offer or in this statement.
[2] The Bid Committee, which has been established by the Board, consists of the
directors of the Board Anders Milton, Bertil Hult and Ulf Mattsson.

[HUG#1485828]